← Russell 3000 cross-section

SRPT Sarepta Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$2.1bn
Revenue TTM
$1.5bn
Net income TTM
$-266m
Free cash flow
$82m
Composite score
45.8
Sector rank
#1625

Valuation

P / E
EV / EBITDA
EV / sales
1.4
FCF yield
3.95%
Earnings yield vs 10-yr
-17.56pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-18.1%
EBITDA margin
-6.7%
ROE
-17.4%
ROIC
-9.0%
Revenue growth
-33.5%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The following tables summarize the components of our net product revenues, by product group, for each of the periods indicated: Net product revenues for the three and six months ended June 30, 2026 decreased by $184.4 million and $465.4 million compared with the same periods in 2025. The decreases were primarily driven by lower ELEVIDYS sales volume, reflecting changes in demand following the safety events that occurred in 2025 and subsequent label update for ELEVIDYS which included only the ambulatory patient population for treatment. …Sarepta Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →